Antibody and T Cell Responses against SARS-CoV-2 Elicited by the Third Dose of BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) Vaccines Using a Homologous or Heterologous Booster Vaccination Strategy

Antibody and T Cell Responses against SARS-CoV-2 Elicited by the Third Dose of BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) Vaccines Using a Homologous or Heterologous Booster Vaccination Strategy

In the present study, antibody and T cell-mediated immune responses elicited by BBIBP-CorV and BNT162b2 vaccines were compared 6 months after the two-dose immunization of healthy individuals. Additionally, antibody and T cell responses after the third dose of BBIBP-CorV or BNT162b2 were compared usi...

Full description

Bibliographic Details
Main Authors: Zsolt Matula, Márton Gönczi, Gabriella Bekő, Béla Kádár, Éva Ajzner, Ferenc Uher, István Vályi-Nagy
Format: Article
Language:English
Published: MDPI AG 2022-03-01
Series:Vaccines
Subjects:
adaptive immunity
anti-SARS-CoV-2 antibodies
IFNγ-producing T cells
IFNγ ELISpot assay
heterologous prime-boost vaccination
Online Access:https://www.mdpi.com/2076-393X/10/4/539

Internet

https://www.mdpi.com/2076-393X/10/4/539

Similar Items